Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

“…We found that PIK3CA mutations were more prevalent in RC, which may attribute to the lesser PFS benefit from cetuximab. Recent consensus has identified four molecular subtypes of colorectal cancer, which differ biologically and are enriched for clinical, pathway and molecular traits [30]. Within two of these subtypes (CMS1 and CMS2), the side of colon has been characterised to be a key clinical feature, further arguing for underlying molecular differences between the right and left colon.…”

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer

“…The need to achieve general classification is very important and a variety of subtypes using the gene expression profile have been proposed. Recently, the CMS (CRC molecular subtypes) classification as a consensus molecular subtype was presented by the Colorectal Cancer Subtyping Consortium (CRCSC) [24]. The CMS classification integrated classifications reported by several researchers.…”

Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer

“…MSI is another hallmark in the CRCSC molecular subtyping [50,54]. MSI-high tumours consist of cells with mismatch repair deficiency that accumulate DNA errors throughout the genome and are associated with a superior outcome.…”

“…EMT is thought to predict for aggressive disease and metastasis. EMT is recognised as a biological hallmark in the Colorectal Cancer Subtyping Consortium (CRCSC) molecular subtypes of CRC, based on cross comparison of all the different studies inclusive of 4562 samples with collated gene expression data [50]. These were mainly stage I to III cancers, and included colon as well as rectal cancers.…”